



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 08 Aug 2016 (#25)

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- NIH Notice of Change in Animal Welfare Assurance Numbering System ([NOT-OD-16-125](#))
- NIH Request for Public Comment on the Proposed Changes to the NIH Guidelines for Human Stem Cell Research and the Proposed Scope of an NIH Steering Committees Consideration of Certain Human-Animal Chimera Research ([NOT-OD-16-128](#))
- Notice of New Funding Strategy for Exploratory/Developmental Grant (R21) Applications at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) ([NOT-EB-16-009](#))

1. Understanding HIV Persistence in Infants

Letter of Intent due date: N/A

Hyperlink: [\(RFA-AI-16-064\)](#)

Type: R01

Application Due Date: December 7, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research in the pathogenesis of perinatal HIV-1 infection by elucidating HIV-1 immune responses in the setting of the infant's evolving immune system and mechanisms of establishment and maintenance of HIV-1 latent viral reservoirs. The goal of this FOA is to gain knowledge to be used in the future development of strategies to induce HIV-1 remission.

Budget: Issuing IC and partner components intend to commit an estimated total of \$ 3,550,000 to fund 3-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Research on Autism Spectrum Disorders

Letter of Intent due date: N/A

Hyperlink: [\(PA-16-388\)](#)
[\(PA-16-386\)](#)
[\(PA-16-387\)](#)

Type: R01
R21
R03

Application Due Date: [Standard dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD).

Budget: **R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R03:** The combined budget for direct costs for the two year project period may not exceed \$100,000. No more than \$50,000 in direct costs may be requested in any single year.



3. Chemical Discovery (CHEM) Award

Letter of Intent due date: 30 days prior to the application due date

Hyperlink:

Type:

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this FOA is to support the development of chemical probes that aid basic research investigations on substance use disorders (SUDs) or identify new lead chemical scaffolds with potential for structure activity relationship (SAR) studies on SUDs. In the long term, it is hoped that these lead chemical scaffolds will provide a greater number of pharmacological tools for basic research and possible drug candidates for medications development.

Budget: For the R21 phase, direct costs are limited to \$275,000 over a two-year project period, with a maximum of \$200,000 allowed in any single year. The R33 phase is limited to \$250,000 in direct costs per year. The total project period may not exceed 4 years. The R21 phase will support milestone-driven exploratory/feasibility “proof of concept” studies for up to 2 years, with a possible, with rapid transition to expedited development work into the R33 phase. The R33 project period can be up to three years, depending upon the requested period for the R21 phase.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements (*click on “PA” to search for further funding opportunities*)

RFA Request for Applications (*click on “RFA” to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)